← 홈

ADC · HER2+ 유방암

273개 · ADC 1032 · Antibody 4683 · CGT 2713 · 다음 갱신 D-8 · 마지막 7월 21일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 273개
ADCBiologicstaleSichuan Baili Pharmaceutical Co…Phase 3

BL-M07D1 (BL-M07D1)

HER2-positive Breast Cancer · HER2

#HER2#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+2
임상시험 18상태 RECRUITING
ADCBiologicstaleFondazione per la Medicina Pers…Phase 3

Pralsetinib (Pralsetinib)

Breast Cancer; Gastrointestinal Cancer · Solid Tumor

#SolidTumor#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+3
효능 ORR 53.8%임상시험 18상태 ACTIVE
ADCBiologicstaleMabwell (Shanghai) Bioscience C…Phase 3

9MW2821 (9MW2821)

Locally Advanced or Metastatic Triple-negative Breast Cancer · HER2

#HER2#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+2
임상시험 17상태 RECRUITING
ADCBiologicstaleDanish Breast Cancer Cooperativ…Phase 3

Abemaciclib with ET (Abemaciclib with ET)

Metastatic Breast Cancer; ER-positive Breast Cancer · HER2

#HER2#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+3
효능 ORR 0%임상시험 17상태 DISCONTINUED
ADCBiologicstaleRemeGenPhase 2

disitamab vedotin (Disitamab Vedotin, RC48, Disitamab Vedotin Tislelizumab)

Her2 Overexpressing High-Risk Non-Muscle Invasive Bladder Urothelial Carcinoma · HER2

#HER2#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
임상시험 17상태 ACTIVE
ADCBiologicstaleRemeGenApproved

disitamab vedotin (Disitamab Vedotin, RC48, Disitamab Vedotin combined with Tislelizumab)

Breast Cancer; Neoadjuvant Therapy · Breast Cancer

#BreastCancer#ADC#Approved#항체약물접합체#antibody-drug-conjugate+2
임상시험 17상태 ACTIVE
ADCBiologicstaleGenentech, Inc.Phase 1

GDC-0941 (GDC-0941)

Metastatic Breast Cancer · Metastatic Breast Cancer

#MetastaticBreastCancer#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+1
임상시험 17상태 ACTIVE
ADCBiologicstaleShanghai JMT-Bio Inc.Phase 2

KN026 (KN026)

HER2-positive Colorectal Cancer; HER2-positive Biliary Tract Cancer · Advanced Breast Cancer

#AdvancedBreastCancer#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
임상시험 17상태 RECRUITING
ADCBiologicstaleSuzhou Suncadia Biopharmaceutic…Phase 2

SHR-A1921 (SHR-A1921)

Advanced Breast Cancer; Metastatic Breast Cancer · HER2

#HER2#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
임상시험 17상태 RECRUITING
ADCBiologicstaleDaiichi SankyoPhase 3

trastuzumab deruxtecan (Enhertu, T-DXd, DS-8201, T-Dxd + Pertuzumab)

HER2 + Breast Cancer · HER2

#HER2#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 1%임상시험 17상태 RECRUITING
ADCBiologicstaleQuantumLeap Healthcare Collabor…Phase 1

ALX148 (ALX148)

HER2-positive Breast Cancer; Metastatic Cancer · HER2

#HER2#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+3
임상시험 15상태 RECRUITING
ADCBiologicstaleAstraZenecaPhase 2

AZD5305 (AZD5305)

Ovarian Cancer; Breast Cancer · Ovarian Cancer

#OvarianCancer#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
임상시험 15상태 RECRUITING
ADCBiologicstaleShanghai Junshi Bioscience Co.,…Phase 2

JS207 (JS207)

Non-squamous Non-small Cell Lung Cancer · HER2

#HER2#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
임상시험 15상태 RECRUITING
ADCBiologicstaleCelgenePhase 1

Valemetostat (Valemetostat)

Aggressive Variant Prostate Carcinoma; Castration-Resistant Prostate Carcinoma · Breast Cancer

#BreastCancer#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+3
효능 ORR 43.7%임상시험 15상태 RECRUITING
ADCBiologicstaleBoehringer IngelheimPhase 2

Zongertinib (Zongertinib)

Metastatic Breast Cancer; Metastatic Gastric Adenocarcinoma · Metastatic Breast Cancer

#MetastaticBreastCancer#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
임상시험 15상태 RECRUITING
ADCBiologicstaleMedSIRPhase 2

CDK4/6i plus ET (CDK4/6i plus ET)

Advanced Breast Cancer; Advanced Breast Carcinoma · Advanced Breast Cancer

#AdvancedBreastCancer#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 19.3%임상시험 14상태 RECRUITING
ADCBiologicstaleAstraZenecaPhase 2

Camizestrant (Camizestrant)

Ovarian Cancer; Breast Cancer · Ovarian Cancer

#OvarianCancer#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 15.7%임상시험 14상태 RECRUITING
ADCBiologicstaleAstraZenecaalonePhase 2

saruparib (AZD8205 and AZD5305, AZD8205 and AZD5305 (saruparib))

Breast Cancer; Biliary Tract Carcinoma · Breast Cancer

#BreastCancer#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+4
임상시험 13상태 RECRUITING
ADCBiologicstaleAstraZenecaalonePhase 2

AZD8205 and AZD5305 (AZD8205 and AZD5305, AZD8205 and AZD5305 (saruparib) and AZD2936 (rilvegostomig), saruparib)

Breast Cancer; Biliary Tract Carcinoma · Breast Cancer

#BreastCancer#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+4
임상시험 13상태 RECRUITING
ADCBiologicstaleCelldex TherapeuticsPhase 2

CDX-011 (CDX-011)

Breast Cancer · Metastatic gpNMB Over-expressing Triple

#MetastaticgpNMBOver-expressingTr#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 21%임상시험 13상태 ACTIVE

7 / 14 페이지

← 이전다음 →